American Thoracic Society - Sanofi Investor Call

Treatment-Emergent Adverse Events in the Safety Population* Placebo (N = 470) Dupilumab (N = 469) Participants with any TEAE, no. (%) 357 (76.0) 363 (77.4) Participants with any treatment-emergent SAE, no. (%) 73 (15.5) 64 (13.6) Participants with any TEAE leading to death, no. (%) 8 (1.7) 7 (1.5) Participants with any TEAE leading to permanent study intervention discontinuation, no. (%) 16 (3.4) 14 (3.0) * The safety population consisted of all patients who received at least one dose or part of a dose of the investigational medicinal product, analyzed according to the treatment received. One patient assigned to the placebo group inadvertently received dupilumab so was included in the dupilumab safety population. ATS 2023 30

View entire presentation